Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neurotech International ( (AU:NTI) ) just unveiled an update.
Neurotech International has initiated an Authorised Prescriber program for its lead therapy, NTI164, in Australia, aimed at expanding access and collecting real-world data to support regulatory submissions and market positioning. Additionally, the company received a Rare Pediatric Disease Designation from the US FDA for NTI164 in treating Rett Syndrome, enhancing its strategic position and regulatory support, while progressing with long-term safety studies and planning further clinical trials.
More about Neurotech International
Neurotech International Ltd is a clinical-stage biopharmaceutical company focused on developing treatments for pediatric neurological disorders. The company is involved in advancing therapies such as NTI164, which targets conditions like Rett Syndrome and autism spectrum disorders, leveraging its proprietary Cannabis sativa strain.
Average Trading Volume: 1,578,474
Technical Sentiment Signal: Sell
Current Market Cap: A$19.42M
See more insights into NTI stock on TipRanks’ Stock Analysis page.